WO2022175752 - TYK2 INHIBITORS AND USES THEREOF
National phase entry:
Publication Number
WO/2022/175752
Publication Date
25.08.2022
International Application No.
PCT/IB2022/000086
International Filing Date
16.02.2022
Title **
[English]
TYK2 INHIBITORS AND USES THEREOF
[French]
INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
Applicants **
SUDO BIOSCIENCES LIMITED
Inventors
PANDEY, Anjali
DIETSCH, Gregory
CHAUDHURI, Bhaskar
MANOJVEER, Seetharaman
THAKKAR, Mahesh
DURAISWAMY, Athisayamani, Jeyaraj
KALVA, Sukesh
Priority Data
63/151,287
19.02.2021
US
63/193,511
26.05.2021
US
63/234,934
19.08.2021
US
63/291,222
17.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5649 | |
| EPO | Filing, Examination, Granting | 83878 | |
| Japan | Filing, Examination, Granting | 4593 | |
| South Korea | Filing, Examination, Granting | 6608 | |
| USA | Filing, Examination, Granting | 33040 |
Total:
133,768
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.[French]
L'invention concerne des composés qui sont des inhibiteurs de TYK2, des procédés de fabrication de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés et des procédés d'utilisation de tels composés dans le traitement d'états pathologiques, de maladies ou de troubles qui pourraient bénéficier de la modulation de l'activité de TYK2.